Metastatic castration-resistant prostate cancer (mCRPC) is among the nastiest variations possible. Death is almost always the end result, and the median survival for men with mCRPC has been less than two years
Read MoreSymptoms and treatment side effects can lead to a greatly reduced quality of life until treatment eventually has its positive effect.
Read More
New healthcare guidelines from the Canadian Task Force on Preventive Health Care recommend that men should not have a PSA test to screen for prostate cancer. A PSA test is a simple blood test that measures the amount of prostate-specific antigen in a man’s blood.
Read More
